|
|
Article: Enzon Beats, Announces Sell-off - Analyst Blog
- Article from:
- Zacks Investment Research - Analyst Blog
- Article date:
- November 10, 2009
- Author:
CopyrightCopyright 2009 Zacks Investment Research. (Hide copyright information)
|
Enzon Beats, Announces Sell-off - Analyst Blog
Enzon
(
ENZN
) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008.
Enzon records revenues from three sources -- products, royalties and contract manufacturing. The three segments recorded a decline of 1%, 6% and 56%, respectively, compared to the year-ago period.
Enzon has four marketed products -- Oncaspar for the treatment of acute lymphoblastic leukemia (ALL); DepoCyt for lymphomatous ...
Related newspaper, magazine, and journal articles:
|
|
Article: Chesapeake Biological Laboratories Announces Collaboration With ...
Business Wire;
July 29, 1997 ;
700+ words
... ... proprietary parenteral product has been signed with Sigma Tau Pharmaceuticals Inc. Under terms of the agreement, Chesapeake Biological ... process-sensitive biopharmaceutical products. Sigma-Tau Pharmaceuticals, Inc. is a wholly owned subsidiary of Sigma-Tau ...
|
|